Compulsive Buying
Conditions
Keywords
Buying, Shopping, Impulse Control
Brief summary
This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.
Detailed description
The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Interventions
DRUGMemantine
10-30mg, by mouth, daily
Sponsors
University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. men and women age 18-65 2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB) 3. buying behavior within 2 weeks prior to enrollment
Exclusion criteria
1. infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB 2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen 3. history of seizures 4. myocardial infarction within 6 months 5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential 6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions; 7. clinically significant suicidality; 8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence 9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID 10. current or recent (past 3 months) DSM-IV substance abuse or dependence; 11. positive urine drug screen at screening 12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline 13. previous treatment with memantine 14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) | from study start to study end (8-weeks) and is Investigator rated | The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms |
Countries
United States
Participant flow
Recruitment details
December 2008 - August 2010
Participants by arm
| Arm | Count |
|---|---|
| Memantine 10-30mg tablets of memantine taken once daily by mouth | 10 |
| Total | 10 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 1 |
Baseline characteristics
| Characteristic | Memantine |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants |
| Age, Continuous | 32 years STANDARD_DEVIATION 12.4 |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)
The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms
Time frame: from study start to study end (8-weeks) and is Investigator rated
Population: Reported scores are Mean and standard deviation for Subjects last visit (Week 8 or last-observation carried forward).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Memantine | Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) | 22 units on a scale | Standard Deviation 4 |